<DOC>
	<DOCNO>NCT01819818</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability paliperidone palmitate 9-week period participant schizophrenia Korea .</brief_summary>
	<brief_title>A Study Observe Safety Tolerability Paliperidone Palmitate ( Invega Sustenna ) Korean Schizophrenic Patients</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-center , prospective ( look forward use observation collect follow participant enrollment ) , non-comparative , non-randomized ( study medication assign chance ) , study . Safety efficacy paliperidone palmitate observe Korean schizophrenic participant 25 week . Approximately 3000 participant observe study study duration 25 week . Safety evaluation include assessment adverse event , concomitant medication , physical examination , psychiatric history .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Participants diagnose schizophrenia Participants prescribe paliperidone palmitate acute maintenance treatment Participants receive paliperidone palmitate approve indication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone palmitate</keyword>
	<keyword>Invega</keyword>
	<keyword>Sustenna</keyword>
	<keyword>Korea</keyword>
</DOC>